Biologic agents targeting IL-17A or IL-17RA have been demonstrated to have considerable clinical impact in the treatment of psoriasis, and this further proves the vital role of IL-17A in psoriasis (Leonardi et al., 2012; Papp et al., 2012; Van De Kerkhof et al., 2016). This evidence concerns the gene IL17RA and psoriasis.